Mortality Similar for Prostate Cancer Therapies.

The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.

Cancer discovery. 2016 Jan 17 [Epub]